Setbacks and Opportunities in Disease-Modifying Therapies in Alzheimer Disease

JAMA Psychiatry. 2020 Jan 1;77(1):7-8. doi: 10.1001/jamapsychiatry.2019.2332.

Authors

Brent P Forester^{1

2}, Regan E Patrick^{1

2}, David G Harper^{1

2}

Affiliations

¹ Division of Geriatric Psychiatry, McLean Hospital, Belmont, Massachusetts.
² Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

PMID: 31532462
DOI: 10.1001/jamapsychiatry.2019.2332

No abstract available

MeSH terms

Alzheimer Disease / drug therapy*
Amyloid beta-Peptides / antagonists & inhibitors
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Treatment Failure

Substances

Amyloid beta-Peptides
Antibodies, Monoclonal, Humanized
aducanumab